Straits Times Index
3,324.53 +17.09 (+0.52%) S&P 500
5,418.61 -2.42 (-0.04%) Dow
38,538.83 -173.38 (-0.45%) Nasdaq
17,621.18 +12.74 (+0.07%) Bitcoin USD
67,018.18 -2,567.27 (-3.69%) CMC Crypto 200
1,418.20 +5.25 (+0.37%)
EDIT Jun 2024 7.500 call
| Previous close | 0.0500 |
| Open | 0.0500 |
| Bid | 0.0000 |
| Ask | 0.1500 |
| Strike | 7.50 |
| Expiry date | 2024-06-21 |
| Day's range | 0.0500 - 0.0900 |
| Contract range | N/A |
| Volume | |
| Open interest | 1.1k |
ZacksEditas (EDIT) Down 2.3% Since Last Earnings Report: Can It Rebound?
Editas (EDIT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
GuruFocus.comEVP, Chief Financial Officer Erick Lucera Sells 22,337 Shares of Editas Medicine Inc
Erick Lucera, the EVP, Chief Financial Officer of Editas Medicine Inc (NASDAQ:EDIT), sold 22,337 shares of the company on May 20, 2024. Following this transaction, the insider has a total of 116,829 shares remaining in the company. Editas Medicine Inc is a biotechnology company focused on developing transformative gene editing therapies to treat a broad range of diseases.
GuruFocus.comDirector Jessica Hopfield Acquires 45,000 Shares of Editas Medicine Inc
On May 13, 2024, Jessica Hopfield, Director at Editas Medicine Inc (NASDAQ:EDIT), purchased 45,000 shares of the company, as reported in the SEC Filing. Editas Medicine Inc (NASDAQ:EDIT) is a biotechnology company focused on developing transformative gene editing therapies to treat a broad range of diseases. Over the past year, the insider transaction history at Editas Medicine Inc shows a trend with 1 insider buy and 11 insider sells.
